No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

PMC Capital Acquires the Assets of Ransom & Randolph Company from Dentsply Sirona

Editor: What To Know

  • Randolph Company, is a leading mission-critical manufacturer and supplier of specialty consumables to the global investment casting industry, serving aerospace, defense, industrial gas turbine, automotive, commercial, jewelry, dental, and art casting markets from Dentsply Sirona, Inc.
  • Randolph will strengthen its focus on our industrial foundry, jewelry and dental lab customer base, while also remaining an important partner to Dentsply Sirona.
  • Randolph looks forward to the future, the roadmap will be to execute a growth model which includes strategic acquisition and organic growth,”.

February 2, 2021

PMC Capital notes that Ransom & Randolph Company, is a leading mission-critical manufacturer and supplier of specialty consumables to the global investment casting industry, serving aerospace, defense, industrial gas turbine, automotive, commercial, jewelry, dental, and art casting markets from Dentsply Sirona, Inc.

Financial terms of the transaction were not disclosed.

The divestment of Ransom & Randolph is part of Dentsply Sirona’s strategy to focus on its core business.

“We are extremely thrilled that this transaction creates an opportunity from which both sides will benefit. As Ransom & Randolph looks forward to the future, the roadmap will be to execute a growth model which includes strategic acquisition and organic growth,” says Michel Tamer, Managing Partner of PMC Capital.

“As an independent business, Ransom & Randolph will strengthen its focus on our industrial foundry, jewelry and dental lab customer base, while also remaining an important partner to Dentsply Sirona. The R&R team and I are eager to serve our customers in new and exciting ways,” says Daniel Nixon, President of Ransom & Randolph.

Founded in 1872, Ransom & Randolph is dedicated to advancing the global investment casting industry. Ransom & Randolph has provided foundries, dental labs, and jewelers with extensive process knowledge, exceptional technical expertise and innovative product technology since the 1800s. By coupling revolutionary product developments with experienced staff, manufacturing and warehousing facilities worldwide, Ransom & Randolph successfully helps customers become casting industry leaders.

CriticalPoint Partners, LLC served as Dentsply Sirona’s exclusive financial advisor for the transaction. 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy